logo
Mizuho's Jared Holz details potential biotech, pharma acquisitions

Mizuho's Jared Holz details potential biotech, pharma acquisitions

CNBC04-06-2025
Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and pharmaceuticals industries.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating
Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating

Yahoo

time10 hours ago

  • Yahoo

Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the . On July 16, Mizuho analyst Graig Suvannavejh raised the firm's price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $5 from $4, maintaining an Outperform rating on the shares. A laboratory technician researching a sample of cells in a biotechnology laboratory. The rating update came after the introduction of NMRA-861 on July 9, when Neumora Therapeutics, Inc. (NASDAQ:NMRA) announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-861 in healthy adult participants with stable schizophrenia. NMRA-861 is a highly potent and selective positive allosteric modulator (PAM) that Neumora Therapeutics, Inc. (NASDAQ:NMRA) is developing for the treatment of schizophrenia and other neuropsychiatric disorders. Mizuho estimates a US launch in 2034, with risk-unadjusted NMRA-861 sales reaching $1.2 billion in 2037. It also sees a favorable risk/reward at current share levels, supporting the optimistic outlook on Neumora Therapeutics, Inc. (NASDAQ:NMRA). Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biotechnology company that integrates neuroscience and data science to offer a precision medicine approach for brain diseases. Its focus is on advancing medicines for therapeutically relevant targets implicated in CNS diseases. While we acknowledge the potential of NMRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Mizuho Raises Microsoft (MSFT) Price Target to $540, Reiterates Outperform on AI Strength
Mizuho Raises Microsoft (MSFT) Price Target to $540, Reiterates Outperform on AI Strength

Yahoo

timea day ago

  • Yahoo

Mizuho Raises Microsoft (MSFT) Price Target to $540, Reiterates Outperform on AI Strength

Microsoft Corporation (NASDAQ:) is one of the . On July 16, Mizuho analyst Gregg Moskowitz raised the price target for the stock from $500 to $540, while maintaining an 'Outperform' rating. The affirmation comes as part of a Q2 earnings preview for the software group. According to Mizuho, Q2 checks by the firm have been good overall, characterized by 'generally healthy' cybersecurity demand and 'very strong' artificial intelligence adoption. However, several contacts have noted that there were a few more delays in deal completions. This may limit fundamental upside in this quarter. Two of Mizuho's favourite stocks to own this quarter are Microsoft and Cyberark. This is especially true ahead of the earnings release for the former. Asif Islam / Microsoft Corporation (NASDAQ:MSFT) provides AI-powered cloud, productivity, and business solutions, focusing on efficiency, security, and AI advancements. While we acknowledge the potential of MSFT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Mizuho Raises Microsoft (MSFT) Price Target to $540, Reiterates Outperform on AI Strength
Mizuho Raises Microsoft (MSFT) Price Target to $540, Reiterates Outperform on AI Strength

Yahoo

timea day ago

  • Yahoo

Mizuho Raises Microsoft (MSFT) Price Target to $540, Reiterates Outperform on AI Strength

Microsoft Corporation (NASDAQ:) is one of the . On July 16, Mizuho analyst Gregg Moskowitz raised the price target for the stock from $500 to $540, while maintaining an 'Outperform' rating. The affirmation comes as part of a Q2 earnings preview for the software group. According to Mizuho, Q2 checks by the firm have been good overall, characterized by 'generally healthy' cybersecurity demand and 'very strong' artificial intelligence adoption. However, several contacts have noted that there were a few more delays in deal completions. This may limit fundamental upside in this quarter. Two of Mizuho's favourite stocks to own this quarter are Microsoft and Cyberark. This is especially true ahead of the earnings release for the former. Asif Islam / Microsoft Corporation (NASDAQ:MSFT) provides AI-powered cloud, productivity, and business solutions, focusing on efficiency, security, and AI advancements. While we acknowledge the potential of MSFT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. 登入存取你的投資組合

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store